Core Insights - Boston Scientific (BSX) is expected to report its fourth-quarter 2025 results on February 4, with earnings per share (EPS) anticipated at 78 cents, reflecting an 11.4% growth year-over-year, and revenues projected at $5.27 billion, indicating a 15.4% increase from the previous year [1][2]. Group 1: Financial Performance - The Zacks Consensus Estimate for BSX's revenues is set at $5.27 billion, which represents a 15.4% increase compared to the same quarter last year [2]. - The consensus for earnings is pegged at 78 cents per share, indicating an 11.4% growth from the year-ago quarter [2]. - BSX has consistently beaten earnings estimates in the past four quarters, with an average surprise of 7.36% [1]. Group 2: Business Segment Performance - The MedSurg division is expected to maintain strong sales momentum, with revenues estimated at $1.80 billion, suggesting an 11.4% year-over-year increase, driven by the Endoscopy and Urology businesses [4][7]. - The Cardiovascular segment is projected to see a 17.5% increase in revenues to $3.46 billion, supported by the uptake of WATCHMAN and FARAPULSE products [9][14]. - The Neuromodulation segment is anticipated to grow, bolstered by the Pain franchise and the acquisition of Nalu Medical, which expands BSX's portfolio in peripheral nerve pain [6]. Group 3: Market Developments - The Endoscopy business within MedSurg is benefiting from the Axios platform and the adoption of innovative technologies like OverStitch and Mantis clip [4]. - The Cardiovascular business is expected to perform well due to strong growth in coronary therapies, particularly from the AGENT Drug-Coated Balloon and the WATCHMAN FLX Pro device's launch in China [10][11]. - The Peripheral Interventions unit is likely to continue its growth trend, despite challenges in the Chinese market, with strong performance in Interventional Oncology & Embolization [13].

Core Insights - Boston Scientific (BSX) is set to report its third-quarter 2025 results on October 22, with expectations of strong performance based on previous earnings surpassing estimates [1][8] Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for BSX's Q3 2025 revenues is $4.97 billion, reflecting an 18.1% increase from the same quarter last year [2] - The consensus estimate for earnings per share (EPS) is 71 cents, indicating a 12.7% growth compared to the prior year's quarter [2][3] Group 2: Performance Drivers - The MedSurg division is expected to maintain solid sales momentum, particularly in the Endoscopy business, driven by the Axios platform and technologies like OverStitch and Mantis clip [4] - The Urology business is anticipated to benefit from core franchises and the expanded indication for Rezum, alongside progress from the Axonics acquisition [5] - Neuromodulation growth is likely supported by the Brain and Pain franchises, with positive trends in Deep Brain Stimulation continuing into Q3 [6] - The Cardiovascular segment is projected to perform well, with strong contributions from the Interventional Cardiology Therapies unit and the completion of the SoniVie acquisition [8][9] - The Peripheral Interventions unit is expected to show strong performance, bolstered by recent acquisitions and growth in both arterial and venous product lines [12] Group 3: Market Position and Trends - The MedSurg revenues are estimated at $1.70 billion, suggesting a 15% year-over-year increase [7] - Cardiovascular revenues are expected to improve by 19.6% year over year to $3.27 billion [13] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook [15]

Core Insights - Boston Scientific (BSX) is expected to report its second-quarter 2025 results on July 23, with prior EPS of 75 cents exceeding estimates by 11.94% [1] - The company has consistently surpassed earnings estimates over the last four quarters, with an average surprise of 8.79% [1] Revenue and EPS Estimates - The Zacks Consensus Estimate for BSX's Q2 2025 revenues is $4.89 billion, reflecting an 18.7% increase year-over-year [2] - The EPS estimate for Q2 2025 is projected at 72 cents, indicating a 16.1% rise compared to the previous year [2] Performance Influencers - The MedSurg division is anticipated to maintain strong sales momentum, particularly in the Endoscopy business, driven by the Axios platform and technologies like OverStitch and Mantis clip [4] - The Urology business is expected to benefit from its core stone management franchise and the integration of the Axonics acquisition [5] - Neuromodulation growth is likely supported by the Brain and Pain franchises, with positive trends from Deep Brain Stimulation and the Intercept product [6] Segment Performance - MedSurg revenues are estimated at $1.68 billion, a 13.1% year-over-year increase [7] - The Cardiovascular unit is projected to perform well, with revenues expected to rise 8.3% year-over-year to $719.95 million [14] - Key contributors to Cardiovascular growth include the AGENT Drug-Coated Balloon and the completion of the SoniVie acquisition [10][11] Earnings Expectations - Boston Scientific has an Earnings ESP of +0.88%, indicating a higher likelihood of beating estimates [15] - The company holds a Zacks Rank of 2 (Buy), suggesting favorable conditions for earnings performance [16]